Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypocretin-1 (orexin A) levels are normal in Huntington's disease.

Literature DB >> 16598614

Hypocretin-1 (orexin A) levels are normal in Huntington's disease.

Christian R Baumann, Martin Hersberger, Claudio L Bassetti.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16598614 DOI： 10.1007/s00415-006-0146-7

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

10 in total

1. Hypocretin (orexin) deficiency in human narcolepsy.

Authors: S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal: Lancet Date: 2000-01-01 Impact factor: 79.321

2. A disorder of rapid eye movements in Huntington's chorea.

Authors: A Starr
Journal: Brain Date: 1967-09 Impact factor: 13.501

3. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors: C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal: Nat Med Date: 2000-09 Impact factor: 53.440

4. Orexin loss in Huntington's disease.

Authors: Asa Petersén; Joana Gil; Marion L C Maat-Schieman; Maria Björkqvist; Heikki Tanila; Inês M Araújo; Ruben Smith; Natalija Popovic; Nils Wierup; Per Norlén; Jia-Yi Li; Raymund A C Roos; Frank Sundler; Hindrik Mulder; Patrik Brundin
Journal: Hum Mol Genet Date: 2004-11-03 Impact factor: 6.150

5. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.

Authors: Christian R Baumann; Yves Dauvilliers; Emmanuel Mignot; Claudio L Bassetti
Journal: Eur Neurol Date: 2004-07-13 Impact factor: 1.710

6. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.

Authors: Vera Popovic; Marina Svetel; Marina Djurovic; Smiljka Petrovic; Mirjana Doknic; Sandra Pekic; Dragana Miljic; Natasa Milic; Jovana Glodic; Carlos Dieguez; Felipe F Casanueva; Vladimir Kostic
Journal: Eur J Endocrinol Date: 2004-10 Impact factor: 6.664

7. Relationship between CSF hypocretin levels and hypocretin neuronal loss.

Authors: Dmitry Gerashchenko; Eric Murillo-Rodriguez; Ling Lin; Man Xu; Laura Hallett; Seiji Nishino; Emmanuel Mignot; Priyattam J Shiromani
Journal: Exp Neurol Date: 2003-12 Impact factor: 5.330

8. Assessment of the nutrition status of patients with Huntington's disease.

Authors: Araceli Trejo; Rosa María Tarrats; Ma Elisa Alonso; Marie-Catherine Boll; Adriana Ochoa; Leora Velásquez
Journal: Nutrition Date: 2004-02 Impact factor: 4.008

Review 9. Epidemiology and clinical features of sleep disorders in extrapyramidal disease.

Authors: Stefania Brotini; Gian Luigi Gigli
Journal: Sleep Med Date: 2004-03 Impact factor: 3.492

10. Nocturnal sleep in Huntington's disease.

Authors: M Wiegand; A A Möller; C J Lauer; S Stolz; W Schreiber; M Dose; J C Krieg
Journal: J Neurol Date: 1991-07 Impact factor: 4.849

10 in total

9 in total

Hypocretin-1 (orexin A) levels are normal in Huntington's disease.

1. Hypocretin (orexin) deficiency in human narcolepsy.

2. A disorder of rapid eye movements in Huntington's chorea.

3. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

4. Orexin loss in Huntington's disease.

5. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.

6. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.

7. Relationship between CSF hypocretin levels and hypocretin neuronal loss.

8. Assessment of the nutrition status of patients with Huntington's disease.

Review 9. Epidemiology and clinical features of sleep disorders in extrapyramidal disease.

10. Nocturnal sleep in Huntington's disease.

1. Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease.

2. Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.

Review 3. G proteins, p60TRP, and neurodegenerative diseases.

Review 4. Interactions of the histamine and hypocretin systems in CNS disorders.

Review 5. Inflammation-sleep interface in brain disease: TNF, insulin, orexin.

Review 6. Chronic sleep disturbance and neural injury: links to neurodegenerative disease.

7. The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease.

8. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease.

Review 9. A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.